Werewolf Therapeutics, Inc. Stock Price, News & Analysis

Werewolf Therapeutics, a biopharmaceutical company focused on cancer treatment, announced that Randi Isaacs, M.D., its Chief Medical Officer, will present at the SVB Securities Global Biopharma Conference. The virtual presentation is scheduled for February 16, 2023, at 8:40 AM ET, during the conference which runs from February 14-16. This event highlights the company's innovative PREDATOR™ platform, designed to stimulate the immune system while minimizing peripheral activity. Werewolf's leading candidates, WTX-124 and WTX-330, are conditionally activated molecules aimed at treating various solid tumors. A link to the live webcast and archived presentation will be available following the event.

Werewolf Therapeutics presented preclinical data on mWTX-330, an innovative IL-12 therapy, at the 37th Annual Meeting of the Society for Immunotherapy of Cancer. The findings suggest mWTX-330 promotes significant anti-tumor activity and immune cell activation in the tumor microenvironment. Additionally, the FDA recently cleared the IND application for WTX-330, paving the way for clinical trials. This therapy aims to treat advanced solid tumors and lymphoma, potentially offering improved efficacy and safety over existing IL-12 therapies.

Werewolf Therapeutics (HOWL) announced significant advancements in its clinical pipeline, including the first patient dosed in a Phase 1/1b trial for WTX-124, targeting advanced solid tumors, with preliminary data expected in Q4 2023. The FDA granted IND clearance for WTX-330, aimed at treating relapsed/refractory tumors. The company reported a cash balance of $140.5 million, sufficient to fund operations through at least Q2 2024, alongside $5 million in collaboration revenue. Net loss for Q3 2022 was reduced to $11.9 million from $13.8 million YoY.

Werewolf Therapeutics (Nasdaq: HOWL) will present preclinical data on its IL-12 INDUKINE molecule, mWTX-330, at the Society for Immunotherapy of Cancer's 37th Annual Meeting on November 11, 2022. This research focuses on tumor-infiltrating lymphocytes and the tumor microenvironment in murine models. Additionally, the management team is set to engage in several investor conferences, including the Jefferies London Healthcare Conference on November 15 and the Piper Sandler Conference on November 29. These events aim to enhance investor relations and share insights into Werewolf's innovative cancer therapies.

Werewolf Therapeutics (Nasdaq: HOWL) will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The pre-recorded presentation will be available on-demand starting 7:00 AM EDT on September 12. Werewolf is focused on conditionally activated therapeutics that stimulate the immune system targeting cancer. Their leading candidates, WTX-124 and WTX-330, aim to improve treatment for solid tumors by activating selectively within the tumor microenvironment while remaining inactive elsewhere.

Werewolf Therapeutics announced the first patient has been dosed in the Phase 1/1b trial for WTX-124, its leading INDUKINE™ molecule targeting IL-2 for treating solid tumors. This multi-center, open-label trial will evaluate WTX-124 alone and with KEYTRUDA® in patients with advanced solid tumors who have not responded to standard care. The innovative design aims to minimize toxicities associated with conventional IL-2 therapy while enhancing anti-tumor activity in the tumor microenvironment. This pivotal milestone reflects Werewolf's commitment to advancing its oncology pipeline.

Werewolf Therapeutics, Inc. (Nasdaq: HOWL) reported significant advancements in its clinical development, including FDA clearance for WTX-124, its lead candidate for treating advanced solid tumors. The IND application for WTX-330 is set for submission in 2H22. The company holds a strong cash position of $145.7 million, expected to sustain operations through Q4 2023. Collaboration revenue reached $4.1 million due to an upfront payment from Jazz Pharmaceuticals, though R&D expenses increased to $13.9 million, leading to a net loss of $14.6 million for Q2 2022.

Werewolf Therapeutics (Nasdaq: HOWL) will participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference on August 9-10, 2022. The company focuses on developing conditionally activated therapeutics to enhance the immune system for cancer treatment. Utilizing its proprietary PREDATOR™ platform, Werewolf aims to create molecules that activate selectively within the tumor microenvironment, minimizing side effects. Key product candidates include WTX-124 and WTX-330, both targeting solid tumors and designed to work with immune checkpoint inhibitors. For more information, visit www.werewolftx.com.

Werewolf Therapeutics (Nasdaq: HOWL), an innovative biopharmaceutical company focused on cancer treatments, announced that Dr. Randi Isaacs, Chief Medical Officer, will participate in a fireside chat at 9:00 AM ET on June 9, 2022, during the Jefferies Global Healthcare Conference in New York. The event is scheduled from June 8-10, 2022. A live webcast will be available, and an archived replay will be accessible for 30 days. Werewolf is pioneering therapeutics that stimulate the immune system using its proprietary PREDATOR™ platform, aiming to enhance treatment for solid tumors.